Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/5015
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIscan, Mumtaz-
dc.contributor.authorAda, Ahmet Oguz-
dc.contributor.authorGuler, Asena-
dc.contributor.authorKunak, Celalettin Semih-
dc.contributor.authorGulhan, Meral-
dc.date.accessioned2024-03-26T06:24:54Z-
dc.date.available2024-03-26T06:24:54Z-
dc.date.issued2017-
dc.identifier.citationIscan, M., Ada, AO., Guler, A., Kunak, CS., Gulhan, M. (2017). CYP1B1*2 and CYP1B1*3 polymorphisms and clinical outcome in non-small cell lung cancer patients. Toxicol. Lett., 280, S239-S239. https://doi.org/10.1016/j.toxlet.2017.07.662en_US
dc.identifier.issn0378-4274-
dc.identifier.issn1879-3169-
dc.identifier.urihttp://dx.doi.org/10.1016/j.toxlet.2017.07.662-
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000425486700594-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/5015-
dc.descriptionWoS Categories: Toxicologyen_US
dc.descriptionWeb of Science Index: Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)en_US
dc.descriptionResearch Areas: Toxicologyen_US
dc.descriptionConference Title: 53rd Congress of the European-Societies-of-Toxicology (EUROTOX)en_US
dc.description.sponsorshipAnkara University [15L0237003, 10A3336002]en_US
dc.language.isoengen_US
dc.publisherELSEVIER IRELAND LTD-CLAREen_US
dc.relation.isversionof10.1016/j.toxlet.2017.07.662en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleCYP1B1*2 and CYP1B1*3 polymorphisms and clinical outcome in non-small cell lung cancer patientsen_US
dc.typearticleen_US
dc.relation.journalTOXICOLOGY LETTERSen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.identifier.volume280en_US
dc.identifier.startpageS239en_US
dc.identifier.endpageS239en_US
Appears in Collections:Dahili Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.